(Publication of an article by Dr. Rasha Fadel Obaid)(Oncolytic virotherapy) Date: 28/08/2019 | Views: 1738

Share in :


Oncolytic virotherapy is a new modality of cancer treatment which uses competent replicating viruses to destroy cancer cells. This field progressed from earlier observations of accidental viral infections causing remission in many malignancies to virus drugs targeting and killing cancer cells. Cancer is one of the leading worldwide causes of death, and despite the consider¬able progress made by researchers in the diversity of cancer treatment methods, the mortality rate from malignant tumors are still alarmingly high, so discouraging cancer growth and reducing its spread is one of the major challenges facing modern medicine. The current goal for developing new therapies for the treatment of cancer is to design or select therapeutic agents that have a high therapeutic index (i.e. high potency against malignant cells) with little or no toxicities to normal cells. Studying virus as a drug has benefits of secure handling of all aspects related to this advancing field. In many ways virus given for treatment is comparable to a drug. The use of replication-competent virus for cancer treatment is a potential therapeutic modality in cancer treatment . The first evidence of the ability of oncolytic viruses to kill cancer cells, talimogene laherparepvec (T-VEC) is a herpes simplex virus (HSV) type 1 (HSV-1) that is the first OV to be approved by the FDA for the treatment of advanced melanoma which initiated recently using in clinical trials ,its development was based on the experiences and success of prior work with oncolytic and intralesional therapies in melanoma. The medical community is very excited about oncolytic viral therapy as it is showing efficacy in many hard-to-treat cancerous tumors such as melanoma

https://www.semanticscholar.org/paper/Correlation-between-live-attenuated-measles-viral-Obaid-Al-Khafaji/5d3c275d9aa8625370cee43a23c6691906f561bd

https://www.iasj.net/iasj?func=article&aId=151718